logo-loader
viewCytoDyn

Full interview: CytoDyn receives IRB approval to treat triple-negative breast cancer patients in expanded access program

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the Vancouver, Washington-based biotech has received approval from the Institutional Review Board for its drug leronlimab to be given to patients with triple-negative breast cancer (TNBC) under an expanded access program.

Pourhassan says the company has recently received interest from just under a dozen patients to enroll within the expanded access program.

Quick facts: CytoDyn

Price: 0.286 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $111.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals positive data on metastatic triple-negative...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has released additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. Pourhassan says representatives from its lab called him crying, revealing...

2 days, 16 hours ago

2 min read